Sugi Predict

Sugi Predict / Compounds / SCHEMBL519468

SCHEMBL519468

SCHEMBL519468

COC(=O)c1cccn1NC(=S)NC(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.52
▸ MAPT P10636 5/20 0.52
▸ KMT2A Q03164 5/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ ALOX12 P18054 2/20 0.52
▸ HPGD P15428 1/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ EPHX1 P07099 4/20 0.47
▸ GAA P10253 3/20 0.47
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ CCR6 P51684 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ GLA P06280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL519964 0.88 SMN1; SMN2 (0.50) ALDH1A1MAPTKMT2AKDM4EMEN1
SCHEMBL13088685 0.86 ALDH1A1 (0.49) ALDH1A1KMT2AKDM4EMEN1ALOX12
SCHEMBL29943719 0.86 EPHX1 (0.50) ALDH1A1KMT2AKDM4EMEN1ALOX12
SCHEMBL2060081 0.84 ALDH1A1 (0.51) ALDH1A1KMT2AKDM4EMEN1ALOX12
SCHEMBL29943759 0.82 SMN1; SMN2 (0.45) ALDH1A1MAPTKMT2AMEN1ALOX12
SCHEMBL19888167 0.81 ALDH1A1 (0.51) ALDH1A1MAPTKMT2AKDM4EMEN1
SCHEMBL18689666 0.80 ALDH1A1 (0.48) ALDH1A1MAPTKMT2AKDM4EMEN1
SCHEMBL522109 0.80 KMT2A (0.48) ALDH1A1MAPTKMT2AKDM4EMEN1
SCHEMBL19222024 0.80 ALDH1A1 (0.50) ALDH1A1MAPTKMT2AKDM4EMEN1
SCHEMBL28042019 0.79 ALDH1A1 (0.52) ALDH1A1MAPTKMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655302-A1 TYRO3 SELECTIVE INHIBITORS AND USES THEREOF The University of North Carolina at Chapel Hill (US) 2025-12-03 — — EP disclosed
WO-2024159097-A1 TYRO3 SELECTIVE INHIBITORS AND USES THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-08-02 — — WO disclosed
CN-111018860-B Pyrrolotriazines and application thereof 中国药科大学 2022-06-10 — — CN disclosed
US-11040981-B2 Pyrrolotriazine compounds and methods of inhibiting TAM kinases SYROS PHARMACEUTICALS, INC. (US) 2021-06-22 — — US disclosed
US-11040981-B2 Pyrrolotriazine compounds and methods of inhibiting TAM kinases SYROS PHARMACEUTICALS, INC. (US) 2021-06-22 — — US disclosed
US-20210147431-A1 PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES SYROS PHARMACEUTICALS INC (US) 2021-05-20 — — US disclosed
US-20210147431-A1 PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES SYROS PHARMACEUTICALS INC (US) 2021-05-20 — — US disclosed
CN-112368285-A Pyrrolotriazine compounds and methods of inhibiting TAM kinase 希洛斯医药品股份有限公司 2021-02-12 — — CN disclosed
US-20200317676-A1 PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES SYROS PHARMACEUTICALS, INC. (US) 2020-10-08 — — US disclosed
EP-3694860-A1 PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES Syros Pharmaceuticals, Inc. (US) 2020-08-19 — — EP disclosed
US-20170296537-A1 AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEROF AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2017-10-19 — — US disclosed
US-20170296537-A1 AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEROF AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2017-10-19 — — US disclosed
EP-3202767-A1 AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND MEDICAL USE THEREOF Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) 2017-08-09 — — EP disclosed
WO-2016144848-A1 PYRROLOTRIAZINE INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME CORP. (US) 2016-09-15 — — WO disclosed
WO-2016144848-A1 PYRROLOTRIAZINE INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME CORP. (US) 2016-09-15 — — WO disclosed
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 — — EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 — — US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 — — US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 — — EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147431-A1 PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES PLK2, MAP3K5, CAMKK2 ALDH1A1 3763/4885MAPT 3445/4885KMT2A 691/4885
US-20200317676-A1 PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES PLK2, MAP3K5, CAMKK2 ALDH1A1 3763/4885MAPT 3445/4885KMT2A 691/4885
US-11040981-B2 Pyrrolotriazine compounds and methods of inhibiting TAM kinases PLK2, MAP3K5, CAMKK2 ALDH1A1 3763/4885MAPT 3445/4885KMT2A 691/4885
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 ALDH1A1 779/4885MAPT 3109/4885KMT2A 114/4885
US-20170296537-A1 AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEROF AND MEDICAL USE THEREOF EGFR, ERBB2, ERBB4 ALDH1A1 1383/4885MAPT 3632/4885KMT2A 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.